Estimated cost-effectiveness of adjuvant nivolumab for resected stage IIB-IIC melanoma in the United States
{{output}}
Background: The CheckMate 76K trial analysis showed that the use of nivolumab as adjuvant therapy in the treatment of patients with resected stage IIB-IIC melanoma reduced recurrence-free survival (RFS). This study aimed to estim... ...
